Despite a phase 3 miss and a difficult regulatory environment, Valneva and Pfizer remain hopeful abo...
HEALTH NEWS
April 01, 2026
Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
Despite a phase 3 miss and a difficult regulatory environment, Valneva and Pfizer remain hopeful about scoring an approval for their Lyme disease shot.
8 views
0 likes
0 comments
Despite a phase 3 miss and a difficult regulatory environment, Valneva and Pfizer remain hopeful about scoring an approval for their Lyme disease shot.
Author: Fierce Biotech
Read Original Article
